Acorda Therapeutics Inc. said Monday the Food and Drug Administration has approved its Inbrija treatment for off episodes in people with Parkinson’s disease.
The company said it expects the treatment to be available by prescription in the first quarter of 2019.
“Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive,” said Todd Sherer, chief executive of the Michael J. Fox Foundation.
“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”
Acorda’s stock, which is still inactive in premarket trade, has lost 31% over the past three months, while the S&P 500 SPX, -2.71% has declined 17%.
Dec. 20, 2018